Researchers Track the Memory of Cancer in Lynch Syndrome | Targeted Oncology

Researchers at MD Anderson Cancer Center have identified a unique immune system signature in the blood of Lynch syndrome carriers, a finding that could lead to new methods for early cancer detection. By sequencing T-cell receptors, scientists were able to distinguish between individuals with Lynch syndrome and the general population, marking a potential shift toward non-invasive cancer interception.

Did You Know? People in the general population have a roughly 5% lifetime risk of developing colorectal cancer, whereas individuals with Lynch syndrome face a risk that can climb as high as 80% depending on their specific genetic mutation.

How the Immune System Acts as a Biological Window

The study, published in Nature Communications, analyzed blood samples from 277 participants to determine how the immune system responds to precancerous lesions. Eduardo Vilar-Sanchez, MD, PhD, and his team sequenced T-cell receptors—the sensors T cells use to identify protein threats—to see if the body learns to recognize abnormal proteins over time.

The data revealed that the immune systems of Lynch syndrome carriers maintain a distinct “fingerprint” of T-cell clones. These clones are developed through exposure to mutated proteins found in polyps and precancerous lesions, even when those lesions are surgically removed before turning into cancer.

Expert Insight: This research suggests that the immune system is far more active in the early stages of disease development than previously understood. By identifying these specific T-cell receptors, clinicians may eventually be able to monitor patient health through routine blood draws rather than relying solely on invasive procedures, potentially shifting the focus of oncology from treatment to early interception.

Matching Blood Signatures to Tissue

To validate their findings, researchers compared T-cell receptors found in the blood against those found in the tumor or precancerous tissue of the same patient. In colorectal cancer cases, up to 41% of the T-cell receptors identified in the tumor were already present in the patient’s blood.

Perhaps more significantly, the team found that 28% of the T-cell receptors identified in non-invasive polyps were also detectable in the blood. This provides evidence that the body begins mounting an immune response long before a lesion is classified as cancer, offering a potential window for earlier clinical intervention.

What May Happen Next in Clinical Practice

A possible next step for this research is the translation of these immune signatures into a practical clinical biomarker. Vilar-Sanchez noted that the team aims to determine if this technology can be used for routine immune surveillance in patients with hereditary syndromes.

“A Promising Vaccine for People Genetically Prone to Early Adult Cancer” | Dr. Eduardo Vilar-Sanchez

If successful, this could allow oncologists to use blood tests to alert patients when the immune system detects something growing, or to monitor how effectively vaccines boost the immune response against potential tumors. While technical hurdles remain, the goal is to provide a tool that helps high-risk patients achieve longer, cancer-free lives.

Frequently Asked Questions

What is the significance of the “previvor” group in this study?
“Previvors” are individuals who carry the Lynch syndrome mutation but have never been diagnosed with cancer. By studying them alongside survivors, researchers were able to establish a classification model that identifies Lynch syndrome carriers regardless of their cancer history.

Why is Lynch syndrome a focus for cancer interception research?
Because Lynch syndrome causes an accelerated rate of colorectal carcinogenesis, it provides an extreme, observable environment for scientists to study how tumors form and how the immune system reacts to them over a lifetime.

How does this research impact vaccine development?
The study provides a framework for tracking how vaccines boost the immune system. Researchers can use T-cell receptor sequencing to see if a vaccine is successfully training the immune system to recognize specific clones that target precancerous lesions.

How do you think blood-based screening might change the way we approach cancer prevention in the future?